Clinical Trial Update: A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating PF-05280014 (trastuzumab-Pfizer) or trastuzumab-EU with paclitaxel for first-line HER2-positive metastatic breast cancer; study complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• PF-05280014 (PF-05280014)
• Trastuzumab-EU (trastuzumab)

Snippet

Sponsor: Pfizer | Conditions: Metastatic Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2018-01-23